Ghia, E. M., Jain, S., Widhopf, G. F., Rassenti, L. Z., Keating, M. J., Wierda, W. G., . . . Kipps, T. J. (2008). Use of IGHV3–21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post–germinal center leukemogenic selection. American Society of Hematology.
Style de citation ChicagoGhia, Emanuela M., et al. Use of IGHV3–21 in Chronic Lymphocytic Leukemia Is Associated With High-risk Disease and Reflects Antigen-driven, Post–germinal Center Leukemogenic Selection. American Society of Hematology, 2008.
Style de citation MLAGhia, Emanuela M., et al. Use of IGHV3–21 in Chronic Lymphocytic Leukemia Is Associated With High-risk Disease and Reflects Antigen-driven, Post–germinal Center Leukemogenic Selection. American Society of Hematology, 2008.